Therapeutic Advances in Chronic Disease

metrics 2024

Empowering clinicians through cutting-edge research.

Introduction

Therapeutic Advances in Chronic Disease is a distinguished open-access journal published by SAGE Publications Ltd, with a focus on innovative research and clinical practices addressing chronic diseases—a field increasingly relevant in today's healthcare landscape. Since its inception in 2010, the journal has committed itself to disseminating high-quality research that informs both theory and practice. With an impressive impact factor and ranked Q1 in Medicine (miscellaneous) in 2023, this journal boasts recognition as one of the top-tier publications in the medical community, placing it in the 79th percentile among its peers. Accessible since 2019, it aims to bridge the gap between cutting-edge research and its application in improving patient outcomes, inviting contributions from researchers, clinicians, and health professionals. The journal's comprehensive scope encompasses various aspects of chronic disease management, making it an invaluable resource for those seeking to advance their understanding of this critical field.

Metrics 2024

SCIMAGO Journal Rank1.03
Journal Impact Factor3.30
Journal Impact Factor (5 years)3.80
H-Index49
Journal IF Without Self3.30
Eigen Factor0.00
Normal Eigen Factor0.70
Influence0.99
Immediacy Index0.50
Cited Half Life3.60
Citing Half Life6.60
JCI0.84
Total Documents658
WOS Total Citations2060
SCIMAGO Total Citations5470
SCIMAGO SELF Citations32
Scopus Journal Rank1.03
Cites / Document (2 Years)3.36
Cites / Document (3 Years)3.61
Cites / Document (4 Years)3.79

Metrics History

Rank 2024

Scopus

Medicine (miscellaneous) in Medicine
Rank #81/398
Percentile 79.65
Quartile Q1

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 118/354
Percentile 66.80
Quartile Q2

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 116/354
Percentile 67.23
Quartile Q2

Quartile History

Similar Journals

Egyptian Journal of Chest Diseases and Tuberculosis

Bridging clinical practice and innovative research in pulmonary medicine.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0422-7638Frequency: 4 issues/year

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

CLINICAL NEPHROLOGY

Exploring innovative treatments in nephrology.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0301-0430Frequency: 12 issues/year

CLINICAL NEPHROLOGY is a prestigious academic journal dedicated to advancing the field of nephrology and related areas of medicine. Published by DUSTRI-VERLAG DR KARL FEISTLE, this journal has been a critical resource for researchers and practitioners since its inception in 1973, with a commitment to disseminating high-quality, peer-reviewed articles that provide insights into clinical practices, innovative treatments, and emerging research in kidney diseases. With an ISSN of 0301-0430, CLINICAL NEPHROLOGY stands out in the medical community, achieving a commendable Q3 ranking in both general medicine and nephrology fields as of 2023. The journal's focus on both clinical application and rigorous scientific inquiry makes it an essential read for healthcare professionals and researchers looking to stay at the forefront of nephrology advancements. Although it operates under a subscription model, its broad scope promises invaluable contributions that address practical challenges and foster interdisciplinary dialogue within the healthcare landscape.

BMJ Open Respiratory Research

Fostering collaboration in the pursuit of respiratory excellence.
Publisher: BMJ PUBLISHING GROUPISSN: Frequency: 1 issue/year

BMJ Open Respiratory Research is a prestigious open access journal published by the BMJ Publishing Group, dedicated to advancing the field of pulmonary and respiratory medicine. Since its inception in 2014, the journal has provided a vital platform for the dissemination of innovative research and clinical findings, boasting an impressive Q1 ranking in its category as of 2023. With a Scopus rank of #35 out of 155 in Pulmonary and Respiratory Medicine, BMJ Open Respiratory Research is recognized for its high-quality content, engaging a global audience of researchers, healthcare professionals, and students. The journal embraces an open access model, ensuring that groundbreaking research is readily available to the community and stakeholders, thereby accelerating knowledge exchange and improving patient care. By focusing on diverse aspects of respiratory health, this journal plays a crucial role in shaping the future of respiratory research and practice.

Respiratory Investigation

Connecting scholars to revolutionize respiratory medicine.
Publisher: ELSEVIERISSN: 2212-5345Frequency: 6 issues/year

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

Advances in Respiratory Medicine

Transforming respiratory health through innovative research.
Publisher: MDPIISSN: 2451-4934Frequency: 6 issues/year

Advances in Respiratory Medicine is a distinguished open-access journal published by MDPI, focusing on the latest research and developments in the field of pulmonary and respiratory medicine. Launched in 2015 and operating out of Switzerland, this journal aims to advance scientific discourse and knowledge by providing a platform for researchers, clinicians, and health professionals. With an impressive ISSN of 2451-4934 and an E-ISSN of 2543-6031, it has made its mark in the academic community, reflected by its impact factor and recognition in the Q3 category for Pulmonary and Respiratory Medicine as of 2023. The journal enjoys a ranking of #95 out of 155 in Scopus within its category, providing authors with visibility and the potential for impactful dissemination of their research. Open access since 2022, it ensures that findings are readily available to all, fostering collaboration and innovation across disciplines. With a commitment to quality and rigor, Advances in Respiratory Medicine invites contributions that push the boundaries of existing knowledge, making it an invaluable resource for anyone dedicated to enhancing respiratory health.

Rational Pharmacotherapy in Cardiology

Exploring the Synergy of Cardiology and Rational Drug Use
Publisher: SOC CARDIOLOGY RUSSIAN FEDERATISSN: 1819-6446Frequency: 6 issues/year

Rational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.

Nephrologie & Therapeutique

Fostering dialogue for a healthier future in nephrology.
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1769-7255Frequency: 7 issues/year

Nephrologie & Therapeutique is a distinguished peer-reviewed journal published by JOHN LIBBEY EUROTEXT LTD, dedicated to the field of nephrology. Since its inception in 2005, this journal has been pivotal in disseminating high-quality research in the areas of kidney disease, renal therapies, and nephrological advancements, and it continues to serve as an essential resource for professionals, researchers, and students alike. With an ISSN of 1769-7255 and an E-ISSN of 1872-9177, the journal is indexed in Scopus and is currently ranked in the third quartile (Q3) within the nephrology category, showing significant contributions to the discipline, despite its current ranking of 64 out of 81. Although Nephrologie & Therapeutique does not operate under an open access model, it nevertheless provides valuable insights and updates on the latest findings and practices in nephrology, making it an important platform for academic discourse in this field. The journal's commitment to advancing knowledge and fostering interdisciplinary dialogue underscores its role as a key player in shaping future research and clinical practices in nephrology.

Internal Medicine

Advancing the Frontiers of Internal Medicine
Publisher: JAPAN SOC INTERNAL MEDICINEISSN: 0918-2918Frequency: 12 issues/year

Internal Medicine is a distinguished peer-reviewed journal published by the Japan Society of Internal Medicine, focusing on the nuanced field of internal medicine. Since its inception in 1974 and with a commitment to advancing medical knowledge, the journal has evolved remarkably, aiming to disseminate high-quality research that contributes to the understanding and treatment of internal diseases. Operating from Tokyo, Japan, it provides an intellectual platform for researchers and clinicians to publish original articles, reviews, and case studies that address various aspects of internal medicine. The journal currently holds a ranking in the Q3 quartile for both Internal Medicine and miscellaneous Medicine categories as of 2023, signifying its growing influence in the medical community. Although not an open-access journal, it remains accessible to a wide audience through institutional subscriptions, enhancing its reach among professionals and students alike. With its commitment to excellence, Internal Medicine serves as an essential resource for those seeking the latest developments and research within this vital medical field.

Thoracic Research and Practice

Driving Innovation in Thoracic Health and Research
Publisher: AVESISSN: Frequency: 6 issues/year

Thoracic Research and Practice is an emerging open access journal published by AVES that aims to advance knowledge in the field of pulmonary and respiratory medicine. Launched in 2022, this journal aspires to provide a platform for innovative research, clinical practices, and advancements in thoracic health. With an E-ISSN of 2979-9139, it caters to a global audience while based in Turkey. Although it currently holds a Q4 category in the 2023 ranking within its field, the journal is dedicated to improving its standing through the inclusion of high-quality, original articles, systematic reviews, and case studies. As it converges years from 2023 to 2024, Thoracic Research and Practice invites researchers, professionals, and students to contribute valuable insights that aim to enhance patient outcomes and propel further exploration in this critical area of medicine.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Fostering Breakthroughs in Medical Science
Publisher: ELSEVIER TAIWANISSN: 0929-6646Frequency: 1 issue/year

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, published by Elsevier Taiwan, stands as a significant academic resource in the field of medical research, particularly within the miscellaneous categories of medicine. With an impressive impact factor and categorized within the Q2 tier of medical journals, it boasts a commendable position in Scopus rankings—#63 out of 636 in General Medicine, placing it in the 90th percentile. Established initially in 1961 and evolving through its open access format since 2016, this journal fosters the dissemination of innovative research, serving an important role in the global medical community. Located in Taipei, Taiwan, it particularly emphasizes studies relevant to the Taiwanese population while welcoming international contributions, enhancing both local and global health discourse. As a trusted platform for researchers, professionals, and students alike, the journal aims to propel advancements in medical science and practice through high-quality peer-reviewed articles. ISSN: 0929-6646, E-ISSN: 1876-0821.